<DOC>
	<DOCNO>NCT00102557</DOCNO>
	<brief_summary>This study compare two treatment oral lichen planus - hydroxychloroquine ( Plaquenil ) tablets clobetasol oral rinse . Oral lichen planus chronic disorder patient painful mouth ulcer interfere meal daily function . It commonly treat topical systemic corticosteroid , drug number side effect , commonly yeast infection , chronic systemic use lead diabetes , osteoporosis , weight gain , complication . Also , lichen planus generally return corticosteroid stop . Clobetasol oral rinse topical steroid commonly use treat oral lichen planus . Hydroxychloroquine , drug originally use treat malaria also approve lupus rheumatoid arthritis , try lichen planus small-scale study evidence benefit . Patients 18 year age old oral lichen planus may eligible study . Pregnant woman exclude . Candidates screen dermatology examination , routine blood test , eye examination , biopsy rule condition similar lichen planus provide tissue research purpose . For biopsy , two small circle tissue 4 mm ( less 1/5 '' ) across surgically remove area lichen planus . Participants randomly assign treatment either hydroxychloroquine clobetasol rinse . Patients assign hydroxychloroquine also take placebo mouth rinse look taste like clobetasol rinse , assign clobetasol also take pill look taste like hydroxychloroquine tablet . This do neither patient study doctor know patient take active medication study complete . Patients take pill daily morning food glass milk 6-month study period use rinse twice day 4 month day 2 month . They may use pain anti-inflammatory medicine topical cream , gel rinse regularly , medication obscure effect study drug complicate interpretation result . They give topical numb medicine part study use Tylenol pain study duration . In addition treatment , participant visit NIH Clinical Center month follow test procedure : - Review pain level , record pain diary - Review drug side effect , - Collection saliva blood sample 2 , 4 6 month - Repeat oral biopsy completion study 6 month evaluate treatment effect - Final examination 8 month determine disease return improve medication stop .</brief_summary>
	<brief_title>Hydroxychloroquine vs. Clobetasol Rinse Treat Oral Lichen Planus</brief_title>
	<detailed_description>This randomize double blind parallel group trial safety efficacy hydroxychloroquine oral lichen planus associate cutaneous genital lesion . The primary objective study test hypothesis oral hydroxychloroquine take 6mg/kg lean weight least effective clobetasol rinse heal ulceration associate erosive form lichen planus . Secondary objective include assessment change salivary tissue proteome plasma , saliva , tissue cytokine profile course treatment hydroxychloroquine clobetasol . We hope allow u gain insight pathophysiology mucosal lichen planus well mechanism action hydroxychloroquine condition . Total surface area oral erosion primary outcome study . We consider 50 % reduction ulcerated area 6 month clinically significant . Secondary outcome include change two lichen planus severity scale , reduction pain level measure visual analogue scale amount topical analgesic use , improvement oral systemic disease-specific generic quality life score . We also assay plasma , saliva , tissue cytokine course study ass dynamic cytokine level disease . We evaluate salivary proteome change associate disease activity use 2D gel electrophoresis mass spectrometric method . The principal study intervention hydroxychloroquine 6 mg/kg lean weight clobetasol 0.05 % oral rinse . Additional allow intervention standard oral topical analgesic rinse need basis . Diagnostic research evaluation include ophthalmologic screen prior enrollment completion study , complete history oral general physical examination , laboratory investigation , saliva collection , oral mucosal biopsy start finish study . The total period time subject spend interventional period trial 6 month . Additional study follow-up period 2 month .</detailed_description>
	<mesh_term>Lichen Planus , Oral</mesh_term>
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<criteria>INCLUSION CRITERIA : Biopsy confirm symptomatic erosive oral lichen planus . World Health Organization histological criterion ( 21 ) combination compatible clinical picture use diagnosis . In questionable case , direct immunofluorescence perform exclude condition . No current treatment hydroxychloroquine immunomodulatory agent . A onemonth washout period require prior enrollment patient take immunomodulatory agent . Prior treatment topical steroid allow . Age great 18 year old . Lichen planus rare patient young 40 year old child especially sensitive effect hydroxychloroquine . Patients sexes racial ethnic group eligible . The presence least one ulcerated oral lesion surface area least 100 sq . mm measure bidirectionally . EXCLUSION CRITERIA : Unable undergo oral biopsy diagnosis Lichen planus ulcerate oral lesion great 100 sq . mm area . Treatment hydroxychloroquine immunomodulatory agent within 1 month randomization . Hepatitis B Hepatitis C infection Significant abnormalities hepatic status measure liver function test ( ALT , AST , AP , bilirubin . ) Mild asymptomatic elevation liver enzymes ( 20 % reference range ) preclude enrollment trial . Significant abnormality renal status measure kidney function test ( creatinine , BUN ) . Uncontrolled diabetes Contraindications hydroxychloroquine clobetasol therapy ( know hypersensitivity , retinopathy prior use , history aplastic anemia agranulocytosis ) . Anemia ( define hemoglobin level 2 standard deviation mean reference value age ) . Granulocytopenia ( define absolute neutrophil count ( ANC ) adult le 1500/mm ( 3 ) ) . Pregnancy lactation . Pregnancy status assess questionnaire . Potentially pregnant patient evaluate plasma HCG test . Patients plan pregnancy exclude . Sexually active female require use contraception prior enrollment study . Every woman childbearing age pregnancy test . Inability unwillingness give write informed consent . Serious concurrent disease ( e.g . myocardial infarction , severe heart failure , severe COPD ) require hospitalization limit life expectancy le 1 year . Psoriasis G6PD deficiency Porphyria Chronic use nonsteroidal antiinflammatory agent agent relieve pain .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Vesiculobullous</keyword>
	<keyword>Mucosal Lesions</keyword>
	<keyword>Oral Health</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Plaquenil</keyword>
	<keyword>Oral Lichen Planus</keyword>
	<keyword>Mouth Lesions</keyword>
	<keyword>Oral Lesions</keyword>
</DOC>